171 related articles for article (PubMed ID: 37000118)
1. A case study of myopericarditis due to immune checkpoint inhibitor therapy: Proposed surveillance and management.
Kuhnly NM; Coviello JS
J Am Assoc Nurse Pract; 2023 May; 35(5):317-321. PubMed ID: 37000118
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitor-Related Myocarditis: Recognition, Surveillance, and Management.
Kuhnly NM; Coviello J
Clin J Oncol Nurs; 2022 Feb; 26(1):54-60. PubMed ID: 35073300
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity of Immune Checkpoint Inhibitors.
Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
Zarifa A; Lopez-Mattei J; Palaskas NL; Iliescu C; Durand JB; Kim PY
Adv Exp Med Biol; 2021; 1342():377-387. PubMed ID: 34972975
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system.
Michel L; Totzeck M; Lehmann L; Finke D
Herz; 2020 Nov; 45(7):645-651. PubMed ID: 32533218
[TBL] [Abstract][Full Text] [Related]
6. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
[TBL] [Abstract][Full Text] [Related]
7. Successful Treatment of Steroid-Refractory Checkpoint Inhibitor Myocarditis with Globulin Derived-Therapy: A Case Report and Literature Review.
Barry T; Gallen R; Freeman C; Agasthi P; Pedrotty D; Yang M; Jokerst CE; Mookadam F; Hardaway BW; LeMond L; Arsanjani R; Larsen C
Am J Med Sci; 2021 Oct; 362(4):424-432. PubMed ID: 33974854
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy.
Delombaerde D; Vervloet D; Franssen C; Croes L; Gremonprez F; Prenen H; Peeters M; Vulsteke C
ESMO Open; 2021 Aug; 6(4):100216. PubMed ID: 34271309
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis.
Liu M; Cheng X; Ni R; Zheng B; Huang S; Yang J
Front Immunol; 2022; 13():1006860. PubMed ID: 36189211
[TBL] [Abstract][Full Text] [Related]
11. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.
Arangalage D; Degrauwe N; Michielin O; Monney P; Özdemir BC
Cancer Treat Rev; 2021 Nov; 100():102282. PubMed ID: 34438238
[TBL] [Abstract][Full Text] [Related]
13. Cardiac MRI Features and Prognostic Value in Immune Checkpoint Inhibitor-induced Myocarditis.
Cadour F; Cautela J; Rapacchi S; Varoquaux A; Habert P; Arnaud F; Jacquier A; Meilhac A; Paganelli F; Lalevée N; Scemama U; Thuny F
Radiology; 2022 Jun; 303(3):512-521. PubMed ID: 35230185
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology.
Chen DY; Huang WK; Chien-Chia Wu V; Chang WC; Chen JS; Chuang CK; Chu PH
J Formos Med Assoc; 2020 Oct; 119(10):1461-1475. PubMed ID: 31444018
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies.
Sun JY; Qu Q; Lou YX; Hua Y; Sun GZ; Sun W; Kong XQ
Int J Cardiol; 2021 Dec; 344():170-178. PubMed ID: 34563597
[TBL] [Abstract][Full Text] [Related]
16. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis.
Peleg Hasson S; Salwen B; Sivan A; Shamai S; Geva R; Merimsky O; Raphael A; Shmilovich H; Moshkovits Y; Kapusta L; Rozenbaum Z; Wolf I; Laufer-Perl M
Clin Res Cardiol; 2021 Jan; 110(1):50-60. PubMed ID: 32296970
[TBL] [Abstract][Full Text] [Related]
17. A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention.
Wei SC; Meijers WC; Axelrod ML; Anang NAS; Screever EM; Wescott EC; Johnson DB; Whitley E; Lehmann L; Courand PY; Mancuso JJ; Himmel LE; Lebrun-Vignes B; Wleklinski MJ; Knollmann BC; Srinivasan J; Li Y; Atolagbe OT; Rao X; Zhao Y; Wang J; Ehrlich LIR; Sharma P; Salem JE; Balko JM; Moslehi JJ; Allison JP
Cancer Discov; 2021 Mar; 11(3):614-625. PubMed ID: 33257470
[TBL] [Abstract][Full Text] [Related]
18. Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries.
Hu X; Wei Y; Shuai X
Front Immunol; 2021; 12():799077. PubMed ID: 34975911
[TBL] [Abstract][Full Text] [Related]
19. Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity.
Liu Q; Yu Y; Lin J; Wang Y; Ai L; Li Q; Wu W; Jin H; Li S; Liu M; Yu S; Liu T
Eur J Cancer; 2021 Nov; 157():10-20. PubMed ID: 34464781
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular events after cancer immunotherapy as oncologic emergencies: Analyses of 610 head and neck cancer patients treated with immune checkpoint inhibitors.
Reyes-Gibby CC; Qdaisat A; Ferrarotto R; Fadol A; Bischof JJ; Coyne CJ; Lipe DN; Hanna EY; Shete S; Abe JI; Yeung SJ
Head Neck; 2024 Mar; 46(3):627-635. PubMed ID: 38151809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]